Selected biomarkers were chosen based on prior evidence linking them to platelet activation (sCD40-L), systemic inflammation (hs-CRP), and endothelial dysfunction (VCAM-1) – all of which are implicated in CMVO pathogenesis. The gene discussed is VCAM1; the disease is endothelial dysfunction.